Current Illinois CancerCare Clinical Trals

Melanoma


A091903 (JIT)

A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma


S2101

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study


Search Again